Julia Brandts1, Dirk Müller-Wieland2. 1. Department of Medicine I, University Hospital RWTH Aachen, Pauwelsstr. 30, 52074, Aachen, Germany. 2. Department of Medicine I, University Hospital RWTH Aachen, Pauwelsstr. 30, 52074, Aachen, Germany. dirmueller@ukaachen.de.
Abstract
PURPOSE OF REVIEW: To summarize latest clinical studies and to put them into perspectives for clinical relevant subgroups and new therapeutic options. RECENT FINDINGS: Have investigated PCSK9 inhibitors in patients with very high cardiovascular risk and insufficient LDL cholesterol lowering under current maximal tolerated lipid-lowering therapy, patients with statin intolerance, or genetic forms of familiar hypercholesterolemia, and patients on LDL apheresis. Purpose of recent cardiovascular endpoint trials has proven cardiovascular benefit of this new approach. PCSK9 inhibition with fully humanized antibodies has proven to be effective, safe, and well-tolerated in reducing cardiovascular risk by LDL cholesterol lowering. Therefore, research interests are to elucidate additional roles and effects of PCSK9 modulation on inflammation and cellular processes of the atherosclerotic plaque and to develop alternative therapeutic strategies addressing PCSK9 as a proven and therefore promising drug target.
PURPOSE OF REVIEW: To summarize latest clinical studies and to put them into perspectives for clinical relevant subgroups and new therapeutic options. RECENT FINDINGS: Have investigated PCSK9 inhibitors in patients with very high cardiovascular risk and insufficient LDL cholesterol lowering under current maximal tolerated lipid-lowering therapy, patients with statin intolerance, or genetic forms of familiar hypercholesterolemia, and patients on LDL apheresis. Purpose of recent cardiovascular endpoint trials has proven cardiovascular benefit of this new approach. PCSK9 inhibition with fully humanized antibodies has proven to be effective, safe, and well-tolerated in reducing cardiovascular risk by LDL cholesterol lowering. Therefore, research interests are to elucidate additional roles and effects of PCSK9 modulation on inflammation and cellular processes of the atherosclerotic plaque and to develop alternative therapeutic strategies addressing PCSK9 as a proven and therefore promising drug target.
Authors: Terry A Jacobson; Matthew K Ito; Kevin C Maki; Carl E Orringer; Harold E Bays; Peter H Jones; James M McKenney; Scott M Grundy; Edward A Gill; Robert A Wild; Don P Wilson; W Virgil Brown Journal: J Clin Lipidol Date: 2014-07-15 Impact factor: 4.766
Authors: Frederick J Raal; Narimon Honarpour; Dirk J Blom; G Kees Hovingh; Feng Xu; Rob Scott; Scott M Wasserman; Evan A Stein Journal: Lancet Date: 2014-10-01 Impact factor: 79.321
Authors: Frederick J Raal; Evan A Stein; Robert Dufour; Traci Turner; Fernando Civeira; Lesley Burgess; Gisle Langslet; Russell Scott; Anders G Olsson; David Sullivan; G Kees Hovingh; Bertrand Cariou; Ioanna Gouni-Berthold; Ransi Somaratne; Ian Bridges; Rob Scott; Scott M Wasserman; Daniel Gaudet Journal: Lancet Date: 2014-10-01 Impact factor: 79.321
Authors: Erik Stroes; David Colquhoun; David Sullivan; Fernando Civeira; Robert S Rosenson; Gerald F Watts; Eric Bruckert; Leslie Cho; Ricardo Dent; Beat Knusel; Allen Xue; Rob Scott; Scott M Wasserman; Michael Rocco Journal: J Am Coll Cardiol Date: 2014-03-30 Impact factor: 24.094
Authors: Ann-Kathrin Vlacil; Jutta Schuett; Volker Ruppert; Muhidien Soufi; Raghav Oberoi; Kinan Shahin; Christian Wächter; Thomas Tschernig; Yu Lei; Fan Liu; Uwe J F Tietge; Bernhard Schieffer; Harald Schuett; Karsten Grote Journal: Basic Res Cardiol Date: 2020-06-25 Impact factor: 17.165